Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical 5% Imiquimod for Vulvar Paget's Disease
NCT02385188Phase 3Completed
- Sponsor
- Radboud University Medical Center
- Start
- May 2015
- Primary completion
- Mar 2018
- Modality
- Nucleic Acid-Directed Small Molecules, Irreversible Covalent Inhibitors, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 3 trial of imiquimod in Vulvar Paget's disease (VPD), sponsored by Radboud University Medical Center. Started May 2015; status: completed.
02
Drugs
imiquimod
03
Conditions
Vulvar Paget's disease (VPD)
Beyond the preview
Go deeper on NCT02385188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02385188.